Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner by Angela C. Hirbe, Özge Uluçkan, Elizabeth.
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.
Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Do HSCs divide asymmetrically?
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
by Kathryn Lagrue, Alex Carisey, David J
by Timothy P. Hughes, and David M. Ross
The Hyperresponsiveness of Cells Expressing Truncated Erythropoietin Receptors Is Contingent on Insulin-Like Growth Factor-1 in Fetal Calf Serum by Jacqueline.
Absence of biologically important Kaposi sarcoma–associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
by Venetia Bigley, Laura E. Spence, and Matthew Collin
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
by Zhenping Zhu Blood Volume 108(6): September 15, 2006
Tax fingerprint in adult T-cell leukemia
Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide.
Transplants for the elderly in myeloma
How I treat elderly patients with myeloma
Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
Mechanisms of HIV-associated lymphocyte apoptosis
Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients by Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla,
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,
Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.
CMV: when bad viruses turn good
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion by Yenan T. Bryceson, Michael E. March, Hans-Gustaf.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma by Alexandra Albertsson-Lindblad, Arne Kolstad,
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
Target recognition–induced NK-cell responses
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index by Chor-Sang Chim, Shing-Yan.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
Anergy: the CLL cell limbo
by John J. Strouse, Megan E. Reller, David G
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,
Actin assembly in response to thrombin.
Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.
by Wendy Lim, Sara K. Vesely, and James N. George
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Biology and treatment of Richter syndrome
Rituximab immunotherapy: it’s getting personal
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.
Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to minimum observed white blood cell.
by Andy Hsu, Hang Quach, Tsin Tai, H. Miles Prince, Simon J
ODM-203 administration results in immune activation in a syngenic model. ODM-203 administration results in immune activation in a syngenic model. Effect.
Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.
Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.
by Holbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, Sarah E. M
Patient Tregs express normal levels of suppression.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Initial treatment of CLL: integrating biology and functional status
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Optimizing therapy for nodal marginal zone lymphoma
Balancing bleeding in brain metastases
Cold agglutinin disease
Presentation transcript:

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel M. Davis Blood Volume 126(1):50-60 July 2, 2015 ©2015 by American Society of Hematology

Lenalidomide treatment increases IFN-γ secretion from NK cells. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide increases the proportion of pNK cells expressing IFN-γ as well as the amount produced per cell. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide lowers the threshold for NK-cell activation through NKG2D and CD16. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide treatment augments opening of cortical actin mesh after CD16 stimulation. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide treatment augments opening of cortical actin mesh after NKG2D and LFA-1 ligation. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide treatment increases NK-cell activation through rituximab. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Lenalidomide augments NK-cell IFN-γ production and cortical actin rearrangements in NK cells isolated from MM patients. Kathryn Lagrue et al. Blood 2015;126:50-60 ©2015 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.